1. Home
  2. REED vs IMNN Comparison

REED vs IMNN Comparison

Compare REED & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reed's Inc.

REED

Reed's Inc.

HOLD

Current Price

$0.91

Market Cap

9.1M

Sector

N/A

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.67

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
IMNN
Founded
1987
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
8.4M
IPO Year
2009
2000

Fundamental Metrics

Financial Performance
Metric
REED
IMNN
Price
$0.91
$1.67
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
6.7K
73.9K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,065,000.00
N/A
Revenue This Year
$18.74
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.47
52 Week High
$5.97
$6.35

Technical Indicators

Market Signals
Indicator
REED
IMNN
Relative Strength Index (RSI) 52.80 N/A
Support Level $0.76 N/A
Resistance Level $1.42 N/A
Average True Range (ATR) 0.11 0.00
MACD 0.04 0.00
Stochastic Oscillator 69.59 0.00

Price Performance

Historical Comparison
REED
IMNN

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: